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Letters to the EditorReply to the Editor:
Annescis, mi fili, quantilla sapientia
mundus regatur?
[Do you not know, my son, how
little wisdom rules the world?]
We thank Dr Gabbay for his letter to
the editor regarding our recent article,
‘‘Deleterious Outcome of No-React-
Treated Stentless Valved Conduits after
Aortic Root Replacement: Why Were
Warnings Ignored?’’1 We understand
that Dr Gabbay is under considerable
pressure because he is not only chief
scientific officer of Shelhigh Inc
(Union, NJ) but also founder and there-
fore directly dependent on the eco-
nomic well-being of the company. We
believe it is human nature that Dr
Gabbay is biased in his perception of
the events surrounding the aortic con-
duit NR-2000C (Shelhigh Inc) and
other products. We, as representatives
of a medical institution, have no interest
in accusing Dr Gabbay, but we merely
worry about the outcome observed in
some of our patients after having used
products from Shelhigh Inc.
In our department within the Aca-
demic Center for Cardiac Surgery
Berne-Basel (1800 cardiac cases1294 The Journal of Thoracic anper year), surgery of the thoracic aorta
accounts for approximately 15% of
the overall surgical volume. This is
due to the high prevalence of aortic
aneurysms in the region and a high
rate of referrals. We perform approxi-
mately 200 to 220 thoracic aortic pro-
cedures per year. We most recently
published our results after surgery on
the thoracic aorta, and these are consis-
tent with contemporary literature.2-4
All patients described in our article1
were operated on by 3 senior staff sur-
geons (T.C., F.E., J.S.), each of whom
has approximately 20 years experience
in the field. None of them were ever
faced with a pathology like the one ob-
served with the NR-2000C aortic tube
valved conduit.
As Dr Gabbay pointed out, a signifi-
cant percentage of these patients were
high risk: A few of them underwent re-
peat surgery because of endocarditis.
We hesitated a long time to attribute
these catastrophic findings to the Shel-
high device, but as the picture became
more consistent, we were able to rule
out other causes of failure, including
surgical technique. Our suspicion that
something was wrong with the device
was emphasized by similar observa-
tions with other Shelhigh products (eg,
the bovine internal thoracic artery used
as peripheral bypass conduit or excep-
tionally as coronary bypass conduit).
We are concerned about the fact
that Dr Gabbay refuses to acknowl-
edge findings as demonstrated in our
article.1 We had several meetings
with Dr Gabbay but it was never pos-
sible to bring our concerns to the point.
The fact that Dr Gabbay talks about
salmonella and tomatoes when we re-
port on patients who may unexpect-
edly die during follow-up or on the
operating table supports our decision
to not further discuss these matters
with the company itself. We send all
explanted material to our in-house cer-
tified pathology and microbiology de-
partment. Although we had severe
concerns with the management of the
company after several visits in Union,
New Jersey, we were terrified afterd Cardiovascular Surgery c May 2009reading the Food and Drug Adminis-
tration (FDA) document: ‘‘Your firm’s
[Shelhigh] Medical Device Reporting
Procedure (Document No. 020047) is
deficient in that: (1) The procedure
lacks a standardized review process
for determining when an event meets
the criteria for submitting an MDR re-
port. (2) There are no procedures for
documentation and record-keeping re-
quirements to determine if information
was evaluated to determine if an event
was reportable and that all events and
subsequent information are submitted
within appropriate timeframes.’’5
Unlike Dr Gabbay, we were
shocked to learn about additional, re-
peated warning letters issued by the
FDA (April 26, 2000, December 14,
2005), because we were not informed
by the company about ongoing prob-
lems and at the time they were brought
to our attention, we had already im-
planted the NR-2000C in more than
100 patients. We assume that the ma-
jority of the readers of the Journal
would be as worried as we are to learn
about such a critical situation. Citation
of the FDA: ‘‘The environmental con-
trols and processes used to manufac-
ture and test devices within your
facility can compromise the sterility
and safety of these products, and there
is therefore a reasonable probability
that use of such products will cause se-
rious adverse health consequences or
death.’’6
We can assure Dr Gabbay and the
readership of the Journal that these
patients receive the closest and most
optimal follow-up possible. However,
we are unable within this short letter
to provide detailed in-hospital data
and follow-up on these patients with
more than 1500 single items per pa-
tient, including repeated imaging and
extensive laboratory work. Dr Gabbay
insists that the issue is site specific, and
indeed that was one of the reasons we
hesitated to issue a formal complaint.
We do think at this point that the cir-
cumstances of a high aortic caseload
together with an unusual follow-up of
almost 100% may have helped to
SHELHIGH BIOPROSTHESIS IN
ACTIVE INFECTIVE
ENDOCARDITIS
To the Editor:
A recent article by Carrel and col-
leagues1 deals with the deleterious
outcome of patients who received
No-React (Shelhigh, Inc, Union,
NJ)–treated stentless valved conduits.
Seven (6.1%) of 115 patients pre-
sented with sudden disastrous find-
ings at the level of the aortic root,
and 4 of them underwent emergency
operations because of disintegration
of the graft along with rupture of the
aortic root. The authors reported that
retrospectively the main findings
were persistent fever or subfebrility
over months. They conclude that the
use of the Shelhigh aortic stentless
prosthesis can no longer be advo-
cated. Is it possible that the authors
have overlooked the patients’ clinical
condition of persisting postoperative
fever, which can lead to the severe
prosthetic endocarditis described in
their article?
We previously reported very good
clinical results from our center using
the above products, especially in pa-
tients with severe active infective
endocarditis. The device was tested
with satisfactory results, and prelimi-
nary follow-up data were published
in 2003 and 2005.2,3 Recent publica-
tions in 2006 and 2008 have shown
satisfactory early and midterm results
with a low reinfection rate in patients
with native or prosthetic endocarditis
complicated by paravalvular abscess,
and the hemodynamic function of the
implants in the aortic position was
comparable with that of homografts.4,5
These articles have perhaps been over-
looked by Carrel and colleagues.
From February 2000 until July
2008, 319 Shelhigh No-React–treated
stentless valves have been implanted
in 305 patients in our institution. Of
these, 17 (5.5%) patients required re-
operations because of reinfection.
The 30-day and 1-, 3-, and 5-year rates
for freedom from reoperation caused
by reinfection were 100%, 94.4% 
1.8%, 87.0%  3.2%, and 83.8% 
4.4%, respectively.4
Analysis of reoperation because of
valve-related complications showed
12 patients who underwent reopera-
tions because of paravalvular leakage,
which is mainly related to endocardi-
tis. The freedom from reoperation be-
cause of valve-related complications
is shown in Figure 1: the 30-day and
1- and 5-year freedom from reopera-
tion rates were 98.9%  0.7%,
97.9%  8.4%, and 92.3%  2.3%,
respectively.
Thus, in our series, there was no
patient who required reoperation, as
Letters to the Editorrecognize this specific problem. We
are deeply worried that we are not
the only ones to observe this sad expe-
rience: A case reported in Germany led
to an unusual procedure and finally re-
sulted in a transplant.7,8 Another simi-
lar observation was made in the United
States after implantation of the device
and led to correspondence with us:
‘‘I read with great interest your report
of 7 patients with bad outcomes after
placement of the Shelhigh stentless
valve-conduit. We have had recent ex-
perience with a man who experienced
valve failure 3 years after placement
of one Shelhigh conduit. A false aneu-
rysm and extensive inflammation were
found at surgery (the surgeon said he
thought there may be an abscess),
and the entire prosthesis had to be re-
moved and replaced with a homograft.
Cultures for bacteria only were nega-
tive. The patient did well postopera-
tively and was discharged on day
17 postoperatively. Our pathologists
also analyzed the tissue and found
extensive acute and chronic inflamma-
tion. On special staining, the wall of
the conduit was infiltrated with numer-
ous acid fast bacteria. Unfortunately,
we did not culture for acid fast organ-
isms so we were not be able to identify
what it is.’’ (P. O’Keefe, Loyola
University Medical Center, personal
communication).
We urge Dr Gabbay not to fight
against reports regarding the NR-
2000C but to encourage him to
shed light on those cases and to rec-
ognize that we had made several at-
tempts to warn him not only about
the aortic valved conduit but also
about several other devices that we
found to give unsatisfactory results
(e.g. the pulmonary conduit and the
bovine IMA).
Thierry Carrel, MDa
Florian S. Schoenhoff, MDa
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Ju¨rg Schmidli, MDa
Department of Cardiovascular
Surgery, University Hospital Bernea
Berne, SwitzerlandThe JournalDepartment of Cardiac Surgery
University of Baselb
Basel, Switzerland
References
1. Carrel T, Schoenhoff F, Schmidli, Stalder M,
Eckstein F, Englberger L. Deleterious outcome of
No-React-treated stentless valved conduits after aor-
tic root replacement: why were warnings ignored?
J Thorac Cardiovasc Surg. 2008;136:52-7. Epub
2008 May 27.
2. Kra¨henbu¨hl ES, Immer FF, Stalder M,
Englberger L, Eckstein FS, Schmidli J, et al. Tech-
nical advances improved outcome in patients under-
going surgery of the ascending aorta and/or aortic
arch: ten years experience. Eur J Cardiothorac
Surg. 2008;34:595-9.
3. Immer FF, Moser B, Kra¨henbu¨hl ES, Englberger L,
Stalder M, Eckstein FS, et al. Arterial access
through the right subclavian artery in surgery of
the aortic arch improves neurologic outcome and
mid-term quality of life. Ann Thorac Surg. 2008;
85:1614-8.
4. Stalder M, Staffelbach S, Immer FF, Englberger L,
Berdat PA, Eckstein FS, et al. Aortic root replace-
ment does not affect outcome and quality of life.
Ann Thorac Surg. 2007;84:775-80.
5. Warning letter from FDA, April 26, 2000. Available
at: http://www.fda.gov/foi/warning_letters/archive/
m3695n.pdf. Accessed September 8, 2008.
6. Letter from FDA, May 2, 2007. Available at: http://
www.fda.gov/ora/frequent/483s/shelhigh/requested_
recall_shellhigh_20070504.pdf. Accessed Septem-
ber 8, 2008.
7. Carrel TP. Another disastrous outcome following
aortic root replacement with the Shelhigh No-react
aortic valved tube. Thorac Cardiovasc Surg.
2008;56:314-5.
8. Tjan TD, Klotz S, Schmid C, Scheld HH. Creation
of a self-made total artificial heart using combined
components of available ventricular assist devices.
Thorac Cardiovasc Surg. 2008;56:51-3.
doi:10.1016/j.jtcvs.2008.10.019of Thoracic and Cardiovascular Surgery c Volume 137, Number 5 1295
